Business
-
Skyepharma has announced a partnership agreement with Mundipharma for global development and commercialization of Skyepharma’s SKP-2076 ICS/LABA/LAMA fixed dose combination MDI. Mundipharma, which already markets Skyepharma’s Flutiform fluticasone propionate/formoterol fumarate MDI in Europe and a… Read more . . .
-
GlaxoSmithKline has recalled two lots of Ventolin HFA metered dose inhalers totaling 128,704 inhalers, according to an FDA enforcement report. The company initiated the voluntary recall on December 3, 2015 due to concerns about insufficient… Read more . . .
-
AstraZeneca has announced that it will acquire Takeda’s respiratory line for $575 million. According to the company, about 200 Takeda employees will transfer to AstraZeneca as part of the deal. The company is citing the… Read more . . .
-
Turing Pharmaceuticals CEO Martin Shkreli has been arrested by the Federal Bureau of Investigations for securities fraud involving illegal stock transactions when he was CEO of Retrophin Pharmaceuticals. Retrophin fired Shkreli in September 2014 and… Read more . . .
-
Teva has acquired exclusive marketing and commercialization rights to Egalet Corporation’s Sprix ketorolac tromethamine nasal spray in Israel, Gaza and the West Bank, Egalet has announced. Sprix nasal spray is used for the short-term treatment… Read more . . .
-
RODES, Inc. and Ligand Pharmaceuticals have announced global license and supply agreements for three products in development using Ligand’s Captisol formulation technology, including intranasal budesonide/azelastine for the treatment of allergic rhinitis. RODES will pay all… Read more . . .
-
US inhaled drug developer InCarda Therapeutics has launched a subsidiary business in Australia in preparation for its first clinical trial, which is scheduled for the first half of 2016, the company said. According to InCarda,… Read more . . .
-
According to the FDA, GlaxoSmithKline has reported that 20 mg and 5 mg dosages of its Imitrex nasal spray for the treatment of migraine headaches will be unavailable until February 2016 due to an API… Read more . . .
-
Turing Pharmaceuticals, which is the subject of several investigations into its pricing strategies, has said that it plans to begin a Phase 1 trial of its TUR-002 intranasal ketamine in the first quarter of 2016.… Read more . . .
-
Insys Therapeutics has announced the resignation of President and CEO Michael L. Babich and the appointment of John N. Kapoor to those positions, effective November 4, 2015. The company also named Daniel Brennan as Executive… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland